1-7 of 7
Sandra Dixon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Clinical Trials & Observations
Jo Howard, Claire Jane Hemmaway, Paul Telfer, D. Mark Layton, John Porter, Moji Awogbade, Timothy Mant, Daniel D. Gretler, Kobina Dufu, Athiwat Hutchaleelaha, Mira Patel, Vincent Siu, Sandra Dixon, Noel Landsman, Margaret Tonda, Joshua Lehrer-Graiwer
Journal: Blood
Blood (2019) 133 (17): 1865–1875.
https://doi.org/10.1182/blood-2018-08-868893
Published: 2019
Journal Articles

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Clark Brown, Carolyn Hoppe, Adlette Inati, Miguel R. Abboud, Winfred Wang, MD, Robert Liem, MD, Gerald Woods, Lewis L. Hsu, Victor R. Gordeuk, MD, Connie Piccone, Richard A. Drachtman, Erica Fong, Sandra Dixon, Margaret Tonda, PharmD, Carla Washington, Joshua Lehrer-Graiwer
Journal: Blood
Blood (2018) 132 (Supplement 1): 509.
https://doi.org/10.1182/blood-2018-99-117510
Published: 2018
Journal Articles

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Carla B Washington, PhD, Michelle Green, PhD, Adlette C. Inati, MD, Clark Brown, MD PhD, Carolyn C Hoppe, MD, Winfred Wang, MD, Ganesh Balaratnam, MD, Sandra Dixon, MS, Erica Fong, Athiwat Hutchaleelaha, PhD, Margaret E Tonda, PharmD, Josh Lehrer, MD MPhil, FACC
Journal: Blood
Blood (2017) 130 (Supplement 1): 980.
https://doi.org/10.1182/blood.V130.Suppl_1.980.980
Published: 2017
Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Clinical Trials & Observations
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja
Journal: Blood
Blood (2016) 127 (26): 3360–3368.
https://doi.org/10.1182/blood-2015-11-683854
Published: 2016
Includes: Supplemental data
Journal Articles

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

James Berenson, MD, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, MD, Morton Coleman, Robert A. Moss, MD, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 373.
https://doi.org/10.1182/blood.V126.23.373.373
Published: 2015
Journal Articles

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

James R. Berenson, MD, Leonard Klein, MD, Robert M. Rifkin, MD, Priti Patel, MD, MS, Sandra Dixon, MS, Ying Ou, PhD, Alan Cartmell, MD
Journal: Blood
Blood (2013) 122 (21): 1934.
https://doi.org/10.1182/blood.V122.21.1934.1934
Published: 2013
Journal Articles

The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials,

Luhua Wang, MD, David S. Siegel, MD, PhD, Andrzej J Jakubowiak, MD, Alvin F. Wong, PharmD, Sandra Dixon, MS, Thomas E Renau, PhD, Ravi Vij, MD
Journal: Blood
Blood (2011) 118 (21): 3969.
https://doi.org/10.1182/blood.V118.21.3969.3969
Published: 2011